Deng Guoying, Wu Zizheng, Zhou Feng, Dai Chenyun, Zhao Jingpeng, Kang Yingjie, Wang Qian, Liu Xijian, Wang Yin, Wang Qiugen
J Biomed Nanotechnol. 2018 Jan 1;14(1):127-138. doi: 10.1166/jbn.2018.2509.
Drug delivery system studies aim to improve nanoparticle (NP) formulation to enable efficient delivery of NPs to tumors. However, NPs must be transported by blood or through direct injection. How NPs leave the circulatory system and how NPs diffuse into a tumor remain unclear, and this uncertainty is a limitation of drug delivery systems. The intimate connection between these questions and metabolism may be related to their biosafety in vivo. Thus, in this study, classical carrier SiO2 NPs were used as typical transport NPs, and fluorescein isothiocyanate (FITC) was used as the representative drug and tracer. As exosome and tunneling nanotubes (TNTs) are the most relevant mechanism for NP transportation and considering the local situation in a tumor, we focused on identifying this phenomenon and investigating TNTs. In conclusion, we effectively demonstrated that NPs can be transferred from cell to cell. Nanotubes may play an important role in this process.
药物递送系统研究旨在改进纳米颗粒(NP)制剂,以实现纳米颗粒向肿瘤的高效递送。然而,纳米颗粒必须通过血液运输或直接注射。纳米颗粒如何离开循环系统以及如何扩散到肿瘤中仍不清楚,这种不确定性是药物递送系统的一个局限。这些问题与新陈代谢之间的密切联系可能与其体内生物安全性有关。因此,在本研究中,经典载体二氧化硅纳米颗粒被用作典型的运输纳米颗粒,异硫氰酸荧光素(FITC)被用作代表性药物和示踪剂。由于外泌体和隧道纳米管(TNTs)是纳米颗粒运输最相关的机制,并且考虑到肿瘤中的局部情况,我们专注于识别这一现象并研究隧道纳米管。总之,我们有效地证明了纳米颗粒可以在细胞间转移。纳米管可能在此过程中发挥重要作用。